Dfn-15
Schizophrenia and Disorders With Psychotic Features
Yale UniversityN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Schizophrenia and Disorders With Psychotic Features cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Flupentixole Technical University of Munich | Phase 4 | BB |
FLUPHENAZINE ENANTHATE IMPURITY B Technical University of Munich | Phase 4 | BB |
ZIPRASIDONE Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 4 | BB |
Thioridazine Technical University of Munich | Phase 4 | B |
CLOPENTHIXOL CIS(Z)-FORM Technical University of Munich | Phase 4 | B |
View all 16 →
Same molecule, other indications
Dfn-15 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →